Top

Published in:

Open Access 01-11-2018 | Original Article

Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy

Authors: Jan C. van der Meijden, Michelle E. Kruijshaar, Laurike Harlaar, Dimitris Rizopoulos, Nadine A. M. E. van der Beek, Ans T. van der Ploeg

Published in: Journal of Inherited Metabolic Disease | Issue 6/2018

Abstract

Objectives

Pompe disease is a progressive metabolic myopathy for which enzyme replacement therapy (ERT) was approved in 2006. While various publications have examined the effects of ERT in classic-infantile patients and in adults, little has been published on ERT in children with non-classic presentations.

Study design

This prospective study was conducted from June 1999 to May 2015. Seventeen patients from various countries participated. Outcome measures comprised muscle function (6-minute walk test, quick motor-function test (QMFT)), muscle strength (hand-held dynamometry; manual muscle testing), and lung function (FVC sitting and supine). For each outcome measure, we used linear mixed-effects models to calculate the difference at group level between the start of therapy and 7 years of ERT. Patients’ individual responses over time were also evaluated.

Results

Eleven males and six females started ERT at ages between 1.1 and 16.4 years (median 11.9 years); 82% of them carried the common c.-32-13T > G GAA gene variant on one allele. At group level, distance walked increased by 7.4 percentage points (p < 0.001) and QMFT scores increased by 9.2 percentage points (p = 0.006). Muscle strength scores seemed to remain stable. Results on lung function were more variable. Patients’ individual data show that the proportion of patients who stabilized or improved during treatment ranged between 56 and 69% for lung function outcomes and between 71 and 93% for muscle strength and muscle function outcomes.

Conclusions

We report a positive effect of ERT in patients with childhood Pompe disease at group level. For some patients, new or personalized treatments should be considered.

Available only for authorised users

A. T. S. Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117CrossRef

American Thoracic Society/European Respiratory Society (2002) ATS/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med 166:518–624CrossRef

Anderson LJ, Henley W, Wyatt KM et al (2014) Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 37:945–952CrossRefPubMed

Angelini C, Semplicini C, Ravaglia S et al (2012) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 259:952–958CrossRef

Baek RC, Palmer R, Pomponio RJ, Lu Y, Ma X, McVie-Wylie AJ (2016) The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa. Mol Genet Metab Rep 8:48–50CrossRefPubMedPubMedCentral

Beenakker EA, van der Hoeven JH, Fock JM, Maurits NM (2001) Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry. Neuromuscul Disord 11:441–446CrossRefPubMed

Bembi B, Pisa FE, Confalonieri M et al (2010) Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 33:727–735CrossRefPubMed

De Filippi P, Saeidi K, Ravaglia S et al (2014) Genotype-phenotype correlation in Pompe disease, a step forward. Orphanet J Rare Dis 9:102CrossRefPubMedPubMedCentral

de Vries JM, van der Beek NA, Hop WC et al (2012) Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 7:73CrossRefPubMedPubMedCentral

de Vries JM, Kuperus E, Hoogeveen-Westerveld M et al (2017) Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. Genet Med 19:90–97CrossRefPubMed

Deroma L, Guerra M, Sechi A et al (2014) Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study. Eur J Pediatr 173:805–813CrossRefPubMed

Engel AG, Gomez MR, Seybold ME, Lambert EH (1973) The spectrum and diagnosis of acid maltase deficiency. Neurology 23:95–106CrossRefPubMed

Gaeta M, Barca E, Ruggeri P et al (2013) Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function. Mol Genet Metab 110:290–296CrossRefPubMed

Gungor D, Reuser AJ (2013) How to describe the clinical spectrum in Pompe disease? Am J Med Genet A 161A:399–400CrossRefPubMed

Hirschhorn R, Reusser AJ (2001) Glycogen storage disease type II: acid alphaglucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3389–3420

Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65–70

Ishigaki K, Murakami T, Nakanishi T, Oda E, Sato T, Osawa M (2012) Close monitoring of initial enzyme replacement therapy in a patient with childhood-onset Pompe disease. Brain Dev 34:98–102CrossRefPubMed

Kishnani PS, Hwu WL, Mandel H et al (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–676CrossRefPubMed

Kishnani PS, Corzo D, Nicolino M et al (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109CrossRefPubMed

Laforet P, Nicolino M, Eymard PB et al (2000) Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 55:1122–1128CrossRefPubMed

Medical Research Council (1978) Aids to the Examination of the Peripheral Nervous System, Memorandum No. 45. Her Majesty’s Stationary Office, London

Mogalle K, Perez-Rovira A, Ciet P et al (2016) Quantification of diaphragm mechanics in Pompe disease using dynamic 3D MRI. PLoS One 11:e0158912CrossRefPubMedPubMedCentral

Pellegrini N, Laforet P, Orlikowski D et al (2005) Respiratory insufficiency and limb muscle weakness in adults with Pompe’s disease. Eur Respir J 26:1024–1031CrossRefPubMed

Pinheiro J BD, Debroy S, Sarkar D, R Core Team (2015) {nlme}: Linear and nonlinear mixed effects models. https://CRAN.R-project.org/package=nlme

Pompe JC (1932) Over idiopathische hypertrofie van het hart. Ned Tijdschr Geneeskd 76:304–311

Porta F, Pagliardini V, Roasio L, Biamino E, Spada M (2015) Playing competitive basketball in face of late-onset pompe disease. Muscle Nerve 51:302–303CrossRefPubMed

Prigent H, Orlikowski D, Laforet P et al (2012) Supine volume drop and diaphragmatic function in adults with Pompe disease. Eur Respir J 39:1545–1546CrossRefPubMed

Quanjer PH, Stanojevic S, Cole TJ et al (2012) Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 40:1324–1343CrossRefPubMedPubMedCentral

R Core Team (2015) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria

Ravaglia S, De Filippi P, Pichiecchio A et al (2012) Can genes influencing muscle function affect the therapeutic response to enzyme replacement therapy (ERT) in late-onset type II glycogenosis? Mol Genet Metab 107:104–110CrossRefPubMed

Regnery C, Kornblum C, Hanisch F et al (2012) 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 35:837–845CrossRefPubMed

Rossi M, Parenti G, Della Casa R et al (2007) Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells. J Child Neurol 22:565–573CrossRefPubMed

Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F (2000) Identification of two subtypes of infantile acid maltase deficiency. J Pediatr 137:283–285CrossRefPubMed

Stepien KM, Hendriksz CJ, Roberts M, Sharma R (2016) Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years. Mol Genet Metab 117:413–418CrossRefPubMed

Strothotte S, Strigl-Pill N, Grunert B et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91–97CrossRefPubMed

Toscano A, Schoser B (2013) Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 260:951–959CrossRefPubMed

Ulrich S, Hildenbrand FF, Treder U et al (2013) Reference values for the 6-minute walk test in healthy children and adolescents in Switzerland. BMC Pulm Med 13:49CrossRefPubMedPubMedCentral

van Capelle CI, Winkel LP, Hagemans ML et al (2008) Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 18:447–452CrossRefPubMed

van Capelle CI, van der Beek NA, Hagemans ML et al (2010) Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord 20:775–782CrossRefPubMed

van Capelle CI, van der Beek NA, de Vries JM et al (2012) The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. J Inherit Metab Dis 35:317–323CrossRefPubMed

van Capelle CI, van der Meijden JC, van den Hout JM et al (2016) Childhood Pompe disease: clinical spectrum and genotype in 31 patients. Orphanet J Rare Dis 11:65CrossRefPubMedPubMedCentral

Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT (2000) Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356:397–398CrossRefPubMed

van den Hout HM, Hop W, van Diggelen OP et al (2003) The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332–340CrossRefPubMed

Van der Beek NA, Hagemans ML, Reuser AJ et al (2009) Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 19:113–117CrossRefPubMed

van der Beek NA, van Capelle CI, van der Velden-van Etten KI et al (2011) Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Mol Genet Metab 104:129–136CrossRefPubMed

van der Beek NA, de Vries JM, Hagemans ML et al (2012) Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 7:88CrossRefPubMedPubMedCentral

van der Ploeg AT, Reuser AJ (2008) Pompe’s disease. Lancet 372:1342–1353CrossRef

van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–1406CrossRefPubMed

van der Ploeg AT, Barohn R, Carlson L et al (2012) Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa. Mol Genet Metab 107:456–461CrossRefPubMed

Van Der Ploeg AT, Kruijshaar ME, Toscano A, et al (2017) European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a ten-year experience. Eur J Neurol 24:768-e31. doi: 10.1111/ene.13285

Wens SC, Ciet P, Perez-Rovira A et al (2015) Lung MRI and impairment of diaphragmatic function in Pompe disease. BMC Pulm Med 15:54CrossRefPubMedPubMedCentral

Winkel LP, Van den Hout JM, Kamphoven JH et al (2004) Enzyme replacement therapy in late-onset Pompe’s disease: a three-year follow-up. Ann Neurol 55:495–502CrossRefPubMed

Wokke JH, Escolar DM, Pestronk A et al (2008) Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 38:1236–1245CrossRefPubMed

Title: Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
Authors: Jan C. van der Meijden
Michelle E. Kruijshaar
Laurike Harlaar
Dimitris Rizopoulos
Nadine A. M. E. van der Beek
Ans T. van der Ploeg
Publication date: 01-11-2018
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 6/2018
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-018-0166-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy

Abstract

Objectives

Study design

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Study design

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Response letter

Correction to: Spectrum of movement disorders and neurotransmitter abnormalities in paediatric POLG disease

Metabolism of amino acid neurotransmitters: the synaptic disorder underlying inherited metabolic diseases

Insulin-resistance in glycogen storage disease type Ia: linking carbohydrates and mitochondria?

Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study

The diagnostic challenge in very-long chain acyl-CoA dehydrogenase deficiency (VLCADD)

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page